A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Oral Single-Doses of LY3526318 on Cinnamaldehyde-Induced Dermal Blood Flow in Healthy Females
Latest Information Update: 18 Mar 2020
At a glance
- Drugs LY 3526318 (Primary)
- Indications Unspecified
- Focus Pharmacodynamics
- Sponsors Eli Lilly and Company
- 16 Mar 2020 Status changed from active, no longer recruiting to completed.
- 03 Feb 2020 Planned End Date changed from 27 Feb 2020 to 6 Mar 2020.
- 03 Feb 2020 Planned primary completion date changed from 27 Feb 2020 to 6 Mar 2020.